Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.
about
L-asparaginase in the treatment of patients with acute lymphoblastic leukemiaBest Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on AsparaginaseDevelopment of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemiaAsparaginase pharmacokinetics and implications of therapeutic drug monitoringStructural and Kinetic Characterization of Guinea Pig l -Asparaginase Type IIIMonitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countriesComparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia.The clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute lymphoblastic leukaemia.L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginasePharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.Identification and structural analysis of an L-asparaginase enzyme from guinea pig with putative tumor cell killing propertiesDrug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.The best way to use asparaginase in childhood acute lymphatic leukaemia--still to be defined?Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.L-asparaginase-induced pancreatic injury is associated with an imbalance in plasma amino acid levels.Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer InstitutErwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.L-Asparaginase Isolated from Phaseolus vulgaris Seeds Exhibited Potent Anti-Acute Lymphoblastic Leukemia Effects In-Vitro and Low Immunogenic Properties In-Vivo.L-Asparaginase Activity in Cell Lysates and Culture Media of Halophilic Bacterial Isolates.A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.Erwinia asparaginase in pediatric acute lymphoblastic leukemia.Asparaginase in the treatment of non-ALL hematologic malignancies.A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study.A critical review on properties and applications of microbial l-asparaginases.Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation.Cloning, expression, purification and characterisation of Erwinia carotovora L-asparaginase in Escherichia coliA clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines.Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients.Asparaginase pharmacology: challenges still to be faced.Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.The optimal use of PEG-asparaginase in relapsed ALL--lessons from the ALLR3 Clinical Trial.Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia.Population pharmacokinetics of native Escherichia coli asparaginase.Glutamine deprivation-mediated cell shrinkage induces ligand-independent CD95 receptor signaling and apoptosis.Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system.Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase.Five-year single-center study of asparaginase therapy within the ALL-BFM 2000 trial.
P2860
Q26738640-8C442622-28AB-4A6B-8ECD-9C769DC7A52FQ26784116-90962AD2-5324-4D8B-99B4-5ADD203C4599Q26825970-D2042E27-A418-4664-A104-2B697743137DQ27026476-977F8C12-F721-43F8-B723-6D08A163BB80Q27682506-A8AF9AE2-B4DD-46C3-A02B-D78107504539Q28362566-BFCB822E-80EF-4500-B162-FA5E3D1CCD3AQ33701864-B1E37700-F69F-46AE-A8E4-33E45AB536F0Q34071686-4A0991B3-4375-46DF-9440-6B8BD18B6E87Q34400424-AEC89775-A4B0-4C45-9A66-DA2BA869DA2CQ34551046-BFB56F94-6C5D-4FB1-9A1F-B9F89BF8E252Q34580270-042479AB-C31A-4671-972D-B3B1009F1560Q35025684-B5A301C2-4BD2-4975-A875-942A79DD79E1Q35178966-11F32A4A-8CE1-4379-BC25-7B77D1E0A74FQ35732108-1A60B47E-31A8-4FCC-9E75-45AD4024E21DQ36470511-5ECC1779-3C38-4E73-86D1-A4C39E68FEEDQ36649984-C181ACD5-4F8C-4D08-8DE5-3B5203E77907Q36678136-B76ECCEF-2740-4146-B2AC-920F419DC9D7Q36996143-C4CE0236-C04F-40B1-80FF-1CF77D82B4BFQ37046992-23B22164-947D-44DE-95B8-3A2E7A9F760DQ37379199-962F7861-1813-4122-ACE2-BFA26C1F87E9Q37491320-58FDCF21-9023-4290-940E-4386918E5B80Q37670065-E44C5BD4-1D51-46DB-A36C-53F5437148D1Q38040418-073B7988-CDFA-4E60-A604-C5F9AA6177ADQ38187018-81DE5B60-1BF1-4C78-86E2-C9406755BD61Q38409519-1E2A35DF-A835-464D-8D5B-D795DC897BBAQ38417141-D59231B8-72AC-4ACA-8D83-86C2A3C63BABQ38696311-C2636A74-4047-4642-A99D-C138A62490E0Q38755617-EC46C657-FC74-40B3-8114-9FD22218E4B3Q38782564-52A9F179-19E9-4E33-9F94-F0ADC8A1E055Q38838632-28BA6EC0-2BC1-4A6E-97A0-A2C47EF4586CQ38934988-FE54B0BB-7B65-4C34-8B3C-88B34E99C481Q39135887-F85D592B-DEE3-4B14-9015-90091679A34AQ39194553-A350D9B4-E268-483C-9A0A-749EF244F3ACQ42544058-7A019C43-D4E2-4136-A709-2951ADE06FA7Q43025556-1ABFCBF5-3F17-4331-BCE2-5809825BE0F0Q43623735-E6B11CC0-6E68-4711-8B34-42948528EA0EQ43765047-206AB75A-3704-453E-A537-5FEF943A5759Q43885619-EC81F0DE-2F17-4BFC-BECC-D306C3B96F67Q43973228-1382AA5E-A817-4012-9B65-03C81EC4DEC2Q44033587-79A6D691-527A-4D77-9AFD-B89CD722A102
P2860
Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Monitoring of asparaginase act ...... ent asparaginase preparations.
@en
Monitoring of asparaginase act ...... ent asparaginase preparations.
@nl
type
label
Monitoring of asparaginase act ...... ent asparaginase preparations.
@en
Monitoring of asparaginase act ...... ent asparaginase preparations.
@nl
prefLabel
Monitoring of asparaginase act ...... ent asparaginase preparations.
@en
Monitoring of asparaginase act ...... ent asparaginase preparations.
@nl
P2093
P1476
Monitoring of asparaginase act ...... ent asparaginase preparations.
@en
P2093
E J Verspohl
G Würthwein
P Schulze-Westhoff
U Nowak-Göttl
P304
P356
10.1016/0959-8049(96)00131-1
P577
1996-08-01T00:00:00Z